Owen O’Connor, MD, PhD, is a Professor of Medicine and Experimental Therapeutics, and the Director of the Center for Lymphoid Malignancies, and Co-Program Director of the Lymphoid Development and Malignancy Program at Columbia University Medical Center.
Dr O’Connor undertook his PhD in Biochemistry and Toxicology from the New York University School of Medicine, followed by a post-doctoral research fellowship in Chemical Engineering. He then went on to obtain his MD from The University of Medicine and Dentistry of New Jersey, followed then by a residency in Internal Medicine at the New York Presbyterian Hospital at Cornell University Medical Center. Following his residency, Dr O’Connor went on to perform his Fellowship in Medical Oncology at the Memorial Sloan Kettering Cancer Center (MSKCC), where he was Chief Fellow, and a completed a fellowship in clinical pharmacology at The New York Presbyterian Hospital at Cornell University.
Speaking on novel small molecule inhibitors in treating blood cancers
Dr O’Conner’s research interests focus on the discovery and development of novel small molecules for the treatment of hematologic malignancies. He is an internationally recognized leader in the discovery and development of new drugs for the treatment of hematologic malignancies, in particular lymphoma.